TherapeuticsMD, Inc.

TXMD

Healthcare Drug Manufacturers Specialty & Generic

TherapeuticsMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 million, up 71.6% from fiscal 2024.

Revenue
−8.72%
EPS
−80.0%
Free cash flow
+104.5%

Quarter to June 2026, against a year earlier

1.74 0.03 +1.75%
Market cap
$20.1M
P/E
n/m
Fwd P/E
18.9×
Dividend yield
—
F-score
6/9
ROIC
−13.8%
Net debt / EBITDA
2.3×
Dividend safety
n/a

TherapeuticsMD, Inc. (TXMD) P/E ratio

Alert me on P/E ratio

TherapeuticsMD, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 138× (June 2026) — the current reading is the lowest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.5× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 0.0× —
Mar 2026 122× —
Dec 2025 0.0× —
Sep 2025 49.3× —
42 more quarters

Against its own ten years

Low 0.0× High 138×
Ten-year median 0.0×
Current reading's percentile 87

P/E ratio against peers

Company P/E ratio
CPHI China Pharma Holdings, Inc. compare n/m
SCYX SCYNEXIS, Inc. compare n/m
TXMD TherapeuticsMD, Inc. n/m
SHPH Shuttle Pharmaceuticals Holdings, Inc. compare n/m
IXHL Incannex Healthcare Inc. compare n/m
BFRI Biofrontera Inc. compare n/m
AYTU Aytu BioPharma, Inc. compare n/m
RMTI Rockwell Medical, Inc. compare n/m
OPTH Optimi Health Corp. compare —
Drug Manufacturers Specialty & Generic industry median 20.5×
Healthcare sector median 24.5×
Market median 17.8×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on TXMD